Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $20.44 : vimarsana.com

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have earned an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price […]

Related Keywords

, Marinus Pharmaceuticals Inc , Nasdaq , Charles Schwab Investment Management Inc , Goldman Sachs Group Inc , Hedge Funds Weigh In On Marinus Pharmaceuticals , Marinus Pharmaceuticals , Analyst Recommendations For Marinus Pharmaceuticals , Marinus Pharmaceuticals Stock Down , Marinus Pharmaceuticals Company Profile , News Ratings For Marinus Pharmaceuticals Daily , Metlife Investment Management , Renaissance Technologies , Get Free Report , Life Investment Management , Schwab Investment Management , Sachs Group , Quantbot Technologies , Pharmaceuticals Stock Down , Get Free , Marinus Pharmaceuticals Daily , Nasdaq Mrns , Mrns , Medical , Ratings , Consensus ,